![Dziyana Kraskouskaya](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Dziyana Kraskouskaya
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Dunad Therapeutics Ltd.
![]() Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Directeur/Bestuurslid | - | - |
Operationeel Directeur | - | - | |
Oprichter | - | - |
Loopbaan van Dziyana Kraskouskaya
Statistieken
Internationaal
Verenigd Koninkrijk | 2 |
Operationeel
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Dunad Therapeutics Ltd.
![]() Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Health Technology |